Dan Jones
Dan Jones
Professor, The Ohio State University
Verified email at
Cited by
Cited by
Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4-and SDF-1-deficient mice
Q Ma, D Jones, PR Borghesani, RA Segal, T Nagasawa, T Kishimoto, ...
Proceedings of the National Academy of Sciences 95 (16), 9448-9453, 1998
Differentiation and reversal of malignant changes in colon cancer through PPARγ
P Sarraf, E Mueller, D Jones, FJ King, DJ DeAngelo, JB Partridge, ...
Nature medicine 4 (9), 1046-1052, 1998
The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment
Q Ma, D Jones, TA Springer
Immunity 10 (4), 463-471, 1999
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
E Jabbour, H Kantarjian, D Jones, M Talpaz, N Bekele, S O'brien, X Zhou, ...
Leukemia 20 (10), 1767-1773, 2006
BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
JA Woyach, AS Ruppert, D Guinn, A Lehman, JS Blachly, A Lozanski, ...
Journal of Clinical Oncology 35 (13), 1437-1443, 2017
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia
E Estey, G Garcia-Manero, A Ferrajoli, S Faderl, S Verstovsek, D Jones, ...
Blood 107 (9), 3469-3473, 2006
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia
F Ravandi, JE Cortes, D Jones, S Faderl, G Garcia-Manero, ...
Journal of clinical oncology 28 (11), 1856-1862, 2010
Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin
F Ravandi, E Estey, D Jones, S Faderl, S O'Brien, J Fiorentino, S Pierce, ...
Journal of Clinical Oncology 27 (4), 504-510, 2009
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation
FJ Giles, J Cortes, D Jones, D Bergstrom, H Kantarjian, SJ Freedman
Blood 109 (2), 500-502, 2007
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic …
F Ravandi, S O'Brien, D Thomas, S Faderl, D Jones, R Garris, S Dara, ...
Blood, The Journal of the American Society of Hematology 116 (12), 2070-2077, 2010
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors
J Cortes, E Jabbour, H Kantarjian, CC Yin, J Shan, S O'Brien, ...
Blood, The Journal of the American Society of Hematology 110 (12), 4005-4011, 2007
Marek disease virus encodes a basic-leucine zipper gene resembling the fos/jun oncogenes that is highly expressed in lymphoblastoid tumors.
D Jones, L Lee, JL Liu, HJ Kung, JK Tillotson
Proceedings of the National Academy of Sciences 89 (9), 4042-4046, 1992
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
J Cortes, M Talpaz, S O'Brien, D Jones, R Luthra, J Shan, F Giles, ...
Clinical Cancer Research 11 (9), 3425-3432, 2005
Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia
JE Cortes, D Jones, S O'Brien, E Jabbour, F Ravandi, C Koller, ...
Journal of Clinical Oncology 28 (3), 398-404, 2010
Lenalidomide therapy in myelofibrosis with myeloid metaplasia
A Tefferi, J Cortes, S Verstovsek, RA Mesa, D Thomas, TL Lasho, ...
Blood 108 (4), 1158-1164, 2006
Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase
JE Cortes, D Jones, S O'Brien, E Jabbour, M Konopleva, A Ferrajoli, ...
Journal of Clinical Oncology 28 (3), 392-397, 2010
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome–positive chronic-phase chronic …
HM Kantarjian, JE Cortes, S O'Brien, R Luthra, F Giles, S Verstovsek, ...
Blood 104 (7), 1979-1988, 2004
Elective cancer surgery in COVID-19–free surgical pathways during the SARS-CoV-2 pandemic: an international, multicenter, comparative cohort study
JC Glasbey, D Nepogodiev, JFF Simoes, O Omar, E Li, ML Venn, PGDME, ...
Journal of Clinical Oncology 39 (1), 66-78, 2021
The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia
D Jones, RJ Benjamin, A Shahsafaei, DM Dorfman
Blood, The Journal of the American Society of Hematology 95 (2), 627-632, 2000
Philadelphia chromosome–positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis
CP Soupir, JA Vergilio, PD Cin, A Muzikansky, H Kantarjian, D Jones, ...
American journal of clinical pathology 127 (4), 642-650, 2007
The system can't perform the operation now. Try again later.
Articles 1–20